Latest news
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
- Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 19 January 2026 Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively
- Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment Press Release, Corporate 15 January 2026 Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment
- Hikma announces CEO change and Board appointment Press Release, Corporate 15 December 2025 Hikma announces CEO change and Board appointment
- Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Press Release, Product 08 December 2025 Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Related content